• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-Effectiveness of SAPIEN  3 Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in German Severe Aortic Stenosis Patients at Low Surgical Mortality Risk
ConclusionsTAVI with SAPIEN  3 appears to be a clinically meaningful, cost-effective treatment option over SAVR for patients with severe symptomatic aortic stenosis and low risk for surgical mortality in Germany.Clinical Trial Registration Numberwww.clinicaltrials.gov identifier: NCT02675114.
Source: Advances in Therapy - January 9, 2023 Category: Drugs & Pharmacology Source Type: research

Risk of Stroke After Transcatheter Aortic Valve Implantation: Epidemiology, Mechanism, and Management
Conclusions: The overall evidences confirm similar or lower rate of stroke in TAVI versus SAVR. Risk predictors for acute stroke after TAVI are generally related to procedural factors, whereas late stroke is mainly associated with patient characteristics, with a variable impact on cognitive function. The optimal choice for the antithrombotic treatment in TAVI for stroke prevention is yet to be determined. Current data do not support routine use of cerebral embolic protection devices during TAVI.
Source: American Journal of Therapeutics - September 1, 2021 Category: Drugs & Pharmacology Tags: Therapeutic Advances Source Type: research

Impact of pre-procedural cerebrovascular events on clinical outcomes after transcatheter aortic valve implantation in patients with severe aortic stenosis.
CONCLUSION: We showed that a history of CVEs in patients with severe AS undergoing TAVI is associated with a higher long-term mortality. PMID: 29468958 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2018 Category: Drugs & Pharmacology Authors: Wiktorowicz A, Kleczynski P, Dziewierz A, Tokarek T, Sorysz D, Bagienski M, Rzeszutko L, Dudek D Tags: Curr Pharm Des Source Type: research

Antithrombotic therapy after TAVR.
Abstract Transvascular aortic valve replacement (TAVR) has emerged as a treatment option in patients with severe aortic stenosis who are inoperable and has recently been evaluated in patients with intermediate surgical risk. The number of procedures is increasing worldwide in parallel with the demographic changes in industrial countries. The risk for cerebral embolism is of main concern and represents a major determinant for prognosis and quality of live after TAVR. The empiric antithrombotic therapy consists of dual antiplatelet therapy (DAPT); however the risk-benefit of this approach is lacking evidence from ra...
Source: Current Vascular Pharmacology - January 17, 2018 Category: Drugs & Pharmacology Authors: Geisler T, Droppa M, Mueller K, Borst O Tags: Curr Vasc Pharmacol Source Type: research

Medication Management of Patients Undergoing Transcatheter Aortic Valve Replacement
This article summarizes key literature supporting the pharmacologic management of patients receiving TAVR. This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 9, 2017 Category: Drugs & Pharmacology Authors: Bethany A. Kalich, J. Erin Ledford, Ian B. Hollis Tags: Review of Therapeutics Source Type: research

Dual or single antiplatelet therapy after transcatheter aortic valve implantation? A systematic review and meta-analysis.
CONCLUSION: DAPT compared to SAPT in patients after TAVI increases incidence of hemorrhagic events with no benefits in terms of thrombotic events and cardiovascular mortality. However, these data must be interpreted cautiously and the choice of DAPT over SAPT must be based on an individual patient characteristic according to medical practice criteria. PMID: 27262328 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 31, 2016 Category: Drugs & Pharmacology Authors: Raut JS, Karuppayil SM, Gazouli M, Vavuranakis M, Siasos G, Zografos T, Oikonomou E, Vrachatis D, Kalogeras K, Papaioannou T, Kolokathis MA, Moldovan C, Tousoulis D Tags: Curr Pharm Des Source Type: research

Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness.
Conclusions The present study demonstrated no significant differences in regards to mortality or stroke between the two therapeutic procedures. However, the cost-effectiveness and long-term efficacy of TAVI may require further investigation. Technological improvement and increased experience may broaden the clinical indication for TAVI for low-intermediate risk patients in the future. PMID: 26891807 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2016 Category: Drugs & Pharmacology Authors: Cao C, Liou KP, Pathan FK, Virk S, McMonnies R, Wolfenden H, Indraratna P Tags: Curr Pharm Des Source Type: research

Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events.
This article aims to comprehensively review the mechanisms of neurological injury per se, the read-outs of cerebrovascular events, and strategies currently used to predict and prevent stroke in transcatheter aortic valve implantation. PMID: 26675314 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 17, 2015 Category: Drugs & Pharmacology Authors: Ghanem A, Naderi AS, Frerker C, Nickenig G, Kuck KH Tags: Curr Pharm Des Source Type: research